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HMR-1826 is a novel prodrug of doxorubicin corresponding to an
original concept for prodrug activation (Muerdter et al, 1997) that
had already been considered for alkylating agents (Connors and
Whisson, 1966). It consists of the standard anticancer drug
doxorubicin, conjugated to glucuronic acid via a spacer (Figure 1).
This relatively non-toxic compound is selectively activated in
necrotic areas of tumours due to the liberation of lysosomal
b-glucuronidase from acute and chronic inflammatory cells in
disintegrating tumour tissue (Bosslet et al, 1998). There is good
evidence that HMR-1826 generates superior therapeutic activity
in several human tumour xenograft models over standard
chemotherapy with doxorubicin (Bosslet et al, 1998).
One of the most important problems that has arisen during the
widespread use of doxorubicin in cancer chemotherapy is related to
its cardiotoxicity. This cardiotoxicity limits the cumulative dose of
doxorubicin that can be administered to a maximum of 500—
550 mg m—2 (Von Hoff et al, 1979), a dose above which the risk
of congestive heart failure increases in unacceptable proportions.
This cumulative dose corresponds to about ten courses of treatment
and prevents the drug from reaching its optimal activity in many
patients, especially breast cancer patients (Mouridsen, 1992).
There has been intensive research in several pharmaceutical
firms to develop either new anthracyclines with significantly less
cardiotoxicity (such as epirubicin), or cardioprotectors able to
decrease the cardiotoxicity of doxorubicin (such as dexrazoxane).
Another approach has concentrated on developing drug-targeting
systems able to increase doxorubicin availability in tumours while
decreasing its systemic availability, in particular accumulation in
cardiac tissue. Liposome-encapsulated doxorubicin (Working and
Dayan, 1996), polymer-bound doxorubicin (Duncan et al, 1998)
and prodrug monotherapy represent important achievements in
this field, but the cardiotoxicity of these new formulations has not
been studied in detail to date.
We have recently developed a functional ex vivo model for the
rapid evaluation of the cardiotoxicity of anthracyclines, and this
model was shown to correctly predict for the comparative
cardiotoxicity of the various molecules presently marketed
including the known activity of dexrazoxane as a cardioprotector
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Summary Cardiotoxicity represents the major side-effect limiting the clinical use of anthracyclines, especially doxorubicin, in cancer
chemotherapy. The use of non-toxic prodrugs, or of liposome-encapsulated drugs, allows a better targeting of the tumours and may, therefore,
improve the tolerance to the treatment. Using the model of isolated perfused rat heart, we have evaluated the cardiotoxicity of a novel prodrug
of doxorubicin, HMR-1826, which consists of the association of doxorubicin to glucuronic acid. We have compared the cardiac effects
(developed pressure, contractility and relaxation of the left ventricle) induced by HMR-1826 to those induced by doxorubicin and Doxil, a
liposomal form of doxorubicin. HMR-1826 was administered intravenously every other day for 11 days at doses of 50–200 mg kg–1 per
injection while doxorubicin was administered according to the same protocol at doses of 1–3 mg kg–1 per injection. Doxorubicin strongly
decreased the cardiac functional parameters at the doses of 2.5 and 3 mg kg–1 per injection. Doxil (3 mg kg–1) and HMR-1826
(50–150 mg kg–1) were largely devoid of cardiotoxicity. HMR-1826 only induced significant alterations of the cardiac function at the highest
dose used (200 mg kg–1 per injection). These alterations were much lower than those of doxorubicin at 2.5 mg kg–1 per injection, despite
similar general toxicity symptoms (weight loss, nose bleeding and diarrhoea) at these respective doses. Thus, HMR-1826 appeared about
100-fold less cardiotoxic than doxorubicin.
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Figure 1 Chemical structure of HMR-1826 (N-(4-b-glucuronosyl-3-
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(Pouna et al, 1996). This model consists in treating rats every two
days for 11 days with anthracyclines, at the dose of 3 mg kg—1 per
day (18 mg kg—1 cumulative dose), intraperitonealy (i.p.). The
myocardial functional performances are studied on the 12th day
by perfusion of the isolated hearts and measure of the pressure
developed in the left ventricle, according to Langendorff (Lorell
et al, 1986).
We have evaluated the cardiotoxicity of HMR-1826 in this ex
vivo model, when administered intravenously (i.v.) every other
day for 11 days at doses of 50—200 mg kg—1 per injection. We show
here that this prodrug has a very low cardiotoxicity, which
appeared only at the highest dose administered, while doxo-
rubicin already exerts a significant cardiotoxicity at the dose of
2.5 mg kg—1 per injection. Liposomal doxorubicin (Doxil), at
3 mg kg—1 per injection, was also devoid of cardiotoxicity. These
results warrant the introduction and evaluation of this new anthra-
cycline prodrug in clinical trials.
MATERIALS AND METHODS
Drugs and chemicals
HMR-1826 was provided by Hoechst Marion Roussel (Marburg,
Germany) as lyophilized powder which was reconstituted extem-
poraneously in 5% mannitol at the concentration of 25 mg ml—1,
and filtered on 0.22 mm filters. Doxorubicin was provided by
Pharmacia & Upjohn (Saint-Quentin-en-Yvelines, France) as the
clinical formulation, which was reconstituted in 0.9% sodium
chloride (NaCl) at the concentration of 1 mg ml—1, divided into
aliquots and kept frozen until use. Liposomal doxorubicin (Doxil¤,
Caelyx¤) was provided by Essex Pharma (M￿nchen, Germany).
All other chemicals and solvents were of the highest grade
commercially available. Special care was taken concerning the
water used for the perfusion medium; we used sterile apyrogenic
water specially prepared for parenteral injections in humans.
Experimental animals
All animal experiments described in this report were done in accor-
dance with the guidelines of Institut National de la Sant￿
et de la Recherche M￿dicale. Male Sprague-Dawley rats aged 10—12
weeks and weighing 300—350 g were obtained from CERJ, Le
Genest-Saint-Isle, France. All experiments included controls
receiving either 0.9% NaCl (control group for doxorubicin and
Doxil) or 5% mannitol (control group for HMR-1826). The drugs
(doxorubicin at 1, 2, 2.5 or 3 mg kg—1 per injection, Doxil at
3 mg kg—1 per injection and HMR-1826 at 50, 100, 150 or
200 mg kg—1 per injection) were administered i.v. via the tail vein on
days 1, 3, 5, 7, 9 and 11 after weighing of the rats and assessment for
possible general toxicity symptoms. On the 12th day the rats were
killed, their hearts were removed and perfused, cardiac functional
parameters were monitored as described below, and the hearts were
weighed at the end of the experiment. The number of rats in each
experimental group varied between 8 and 12 in all cases, except for
the rats receiving HMR-1826 at doses of 50, 150 and 200 mg kg—1
per injection, which were four or five in each group.
Perfusion of isolated rat hearts
Rats were heparinized i.p. (500 IU per 100 g body weight) and
anaesthetized with diethylether. The heart was quickly excised and
soaked in Krebs—Henseleit solution at 4°C. Coronary perfusion
was initiated through a short cannula in the aortic root and main-
tained at a constant pressure of 90 mmHg in a non-recirculating
way by the Langendorff technique as described by Lorell et al
(1986). Perfusion pressure was measured by a P23Db transducer
(Bentley Trantec) connected to the aortic infusion cannula. The
heart was electrically paced at a rate of 300 beats per min (5 Hz)
through stimulator-activated stainless steel electrodes placed on
the heart. A latex balloon attached to one end of a polyethylene
catheter was placed in the left ventricle through the mitral valve.
The catheter was filled with water and the other end was linked to
an electronic amplifier (Thomson Medical) via a second P23Db
transducer.
The coronary perfusion pressure and the left ventricular
pressure were recorded on a computer that allowed continuous
monitoring of heart rate, left ventricular systolic pressure
(LVSP), left ventricular end-diastolic pressure (LVEDP), left
ventricular developed pressure (LVDP = LVSP — LVEDP) and
the maximal and minimal first derivatives of LVDP as a function
of time (LV(dP/dt)max and LV(dP/dt)min) respectively. The
perfusate consisted in a modified Krebs—Henseleit buffer, pH
7.4, containing NaCl (118 mM), potassium chloride (4.7 mM),
magnesium sulphate (1.2 mM), KH2PO4 (1.2 mM), sodium
hydrogencarbonate (25 mM), glucose (11 mM), calcium chloride
(0.95 mM) and insulin (10 IU l—1). It was continuously bubbled
with a mixture of 95% oxygen 5% carbon dioxide and main-
tained at 37°C. The latex balloon inserted in the left ventricle
was periodically dilated with distilled water in order to produce a
LVEDP of 5—6 mmHg. After 30- to 45-min stabilization, neces-
sary to reach the maximal functional cardiac values, the above
parameters were recorded.
Anthracycline accumulation
Samples were obtained from the hearts of three rats treated
according to the same protocol with doxorubicin (1 mg kg—1 per
injection) and of five rats treated with HMR-1826 (100 mg kg—1
per injection) for the measure of cardiac accumulation of doxo-
rubicin. These samples were homogenized in physiological saline
(2 ml for 100 mg tissue) with a tissue homogenizer (Ultra-
Turrax). After addition of an adequate amount of internal stan-
dard (daunorubicin) and of 0.5 ml borate buffer (50 mM, pH 9.8)
to 0.5 ml of the homogenate, anthracyclines and metabolites were
extracted with 9 ml of chloroform—methanol 4/1 (v/v), according
to Baurain et al (1979). After mixing and centrifuging (10 min at
3000 g), the solvent layer was recovered, evaporated to dryness
and reconstituted with 200 ml methanol. Calibration curves were
obtained after incubating heart homogenates with doxorubicin in
vitro for 15 min at room temperature. A good linearity was
obtained from 0.015 to 1.5 nmol g—1 tissue. Chromatography was
performed on a Radial-Pak C18 column (Waters Associates,
Saint-Quentin-en-Yvelines, France) inserted in a compression
device. The solvent was a mixture of ammonium formate buffer
(60 mM, pH 4.0) and acetonitrile (68/32) delivered at 2 ml min—1.
Detection was achieved with a laser-induced fluorescence
recorder (Zeta Technology, Toulouse, France) with excitation and
emission wavelengths set at 488 and 550 nm respectively.
Retention times and peak areas were recorded with a micro
computer using the PC1000 software (Thermo Quest, Les Ulis,
France).26 D Platel et al
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Statistical analysis of the data
Statistical comparisons between untreated and treated groups were
made by Student￿s t-test after ANOVA assumption of the validity
of t-test; all data in the tables are expressed as mean value ± s.d.
Statistical significance was determined as a P-value below 0.05.
RESULTS AND DISCUSSION
The general toxicity of the treatment with doxorubicin and HMR-
1826 could be evaluated by the decrease in body weight. There was
a parallel decrease in body weight induced by the two drugs, with a
shift between the two curves: a similar loss was obtained with
doxorubicin at the dose of 2.5 mg kg—1 per injection and HMR-1826
at 200 mg kg—1 per injection. The equivalent dose ratio was there-
fore around 80 for this parameter. When considering other general
toxicity symptoms, it appeared that doxorubicin provided nose
bleeding at the dose of 2 mg kg—1 per injection and beyond, and
diarrhoea from the dose of 2.5 mg kg—1 per injection. HMR-1826
induced nose bleeding at 150 mg kg—1 per injection and both nose
bleeding and diarrhoea at 200 mg kg—1 per injection. For these
general toxicity symptoms, the equivalent dose ratio HMR-
1826/doxorubicin also appeared to be around 75—80. Doxil at 3 mg
kg—1 per injection provided a similar weight loss and similar general
toxicity symptoms as doxorubicin at 2 mg kg—1 per injection.
The cardiac toxicity of the treatments could be evaluated by
three parameters: the left ventricular developed pressure and the
maximal and minimal first derivatives of the left ventricular pres-
sure as a function of time, which evaluate the contractility and the
relaxation properties of the left ventricle respectively. Figures 2—4
represent these parameters as a function of the dose administered.
Doxorubicin induced significant alterations of the three parameters
from the dose of 2.5 mg kg—1 per injection. At this dose level, the
decrease in LVDP, LV(dP/dt)max and LV(dP/dt)min were of about
50% of the control values. At 3 mg kg—1 per injection, the alter-
ations were extremely important and reached 70% of the control
values. In comparison, Doxil induced no significant alterations of
cardiac functional parameters at the dose of 3 mg kg—1 per injec-
tion, and HMR-1826 induced significant alterations only at the
highest dose tested. However at this dose (200 mg kg—1 per injec-
tion), the decrease in the functional parameters reached no more
than 30%, still significantly less than with the dose of doxorubicin
of 2.5 mg kg—1 per injection. For cardiotoxicity, the equivalent dose
ratio HMR-1826/doxorubin appears, therefore, to be higher than
the equivalent dose ratio for general toxicity. This means that, at
the dose providing the same general toxicity, HMR-1826 is signifi-
cantly less cardiotoxic than doxorubicin. Furthermore, since a dose
of 200 mg kg—1 administered once every 3 weeks has been shown
to significantly inhibit tumour xenografts (personal communica-
tion), this finding of significantly less cardiotoxicity on an every
other day schedule may have clinical implications for a less
frequent schedule.
Doxorubicin accumulation was measured in the heart of rats
treated with the same protocol at doses of doxorubicin and Doxil
of 1 mg kg—1 per injection, and of HMR-1826 of 100 mg kg—1 per
injection. This accumulation on the 12th day amounted to
4.4  ± 0.8 nmoles g—1 tissue for doxorubicin, which was 30 times
higher than the accumulation obtained after Doxil treatment
(0.14 ± 0.03 nmoles g—1 tissue, P < 0.01 vs doxorubicin) and
threefold higher than following HMR-1826 administration
(1.5 ± 0.2 nmoles g—1 tissue, P < 0.01 vs doxorubicin and P< 0.0001
vs Doxil). Since heart doxorubicin likely originates from circu-
lating free doxorubicin released from the vehicle, this would mean
that only 0.3% of the glucuronide injected generates free doxoru-
bicin in the circulation. Doxorubicinol concentration never
exceeded 10% of doxorubicin concentration in all three groups and
did not significantly differ between groups. These preliminary data
suggest that the lower cardiotoxicity of HMR-1826 as compared to
doxorubicin may be due to its reduced accumulation in the heart.
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Figure 2 Effect of drug treatments on the left ventricular developed
pressure. (A) Doxorubicin (l l) and Doxil (n). (B) HMR-1826. Student’s t-test:
treated vs control rats: †††P < 0.001; ‡P < 0.0001; Doxil at 3 mg kg–1 vs
doxorubicin at 3 mg kg–1: *P < 0.0001
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Figure 3 Effect of drug treatments on the left ventricular contractility.
(A) Doxorubicin (l l) and Doxil (n). (B) HMR-1826. Student’s t-test: treated vs
control rats: †P < 0.05; ‡P < 0.0001; Doxil at 3 mg kg–1 vs doxorubicin at
3 mg kg–1: *P< 0.0001
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Figure 4 Effect of drug treatments on the left ventricular relaxation.
(A) Doxorubicin (l l) and Doxil (n). (B) HMR-1826. Student’s t-test: treated vs
control rats: †††P < 0.001; ‡P < 0.0001; Doxil at 3 mg kg–1 vs doxorubicin
at 3 mg kg–1: *P < 0.0001Cardiotoxicity of anthracycline prodrugs 27
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In a comparison of the anti-tumour activities of doxorubicin and
HMR-1826, Bosslet et al (1998) showed a significantly higher
inhibition of tumour growth in most of the 20 human xenograft
models explored, for dose ratios HMR-1826/doxorubicin between
25 and 133. It appears, therefore, that this new drug formulation
widens the therapeutic window of doxorubicin.
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